Notice of Annual General Meeting 22 April 2016
(Oslo, Norway, 31 March 2016) The Annual General Meeting 2016 of Bionor Pharma ASA will be held on Friday 22 April 2016 at 12:00 hours at Hotel Continental, Stortingsgaten 24/26, Oslo, Norway, “Møterom 4”.
The notice of the Annual General Meeting 2016 is attached hereto and includes detailed registration and proxy instructions.
All relevant documents a can be found on www.bionorpharma.com and incudes:
- Notice of Annual General Meeting
- Nomination Committee Proposal
- Board statement on the determination of salary and other remuneration to Executive Management
- Annual Report 2015
Please click here for online registration of attendance and advance voting.
Please note that to attend the Annual General Meeting, attendants must be registered shareholders five working days prior to the meeting – 15 April 2016.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine
Vacc-4x in combination with other medicines toward a functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV ’Shock & Kill’ trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor is currently planning BIOSKILL, a proof-of-concept Phase II trial, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company. Bionor is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.